Abstract
At the outset, it is important to make a clear distinction between prognostic factors and predictive indices. Prognostic factors provide us with an estimate of the rate of relapse and death for defined subpopulations of women with breast cancer. Predictive indices are supposed to allow us to determine which subgroup of patients respond preferentially to particular types of treatment. Rational selection of adjuvant systemic therapy is therefore based on two quite separate calculations.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Reference
Scottish Cancer Trials Breast Group and ICRF Breast Unit, Cuy’s Hospital, London (1993) Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet 341: 8856
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Baum, M. (1996). Summary. In: Senn, H.J., Gelber, R.D., Goldhirsch, A., Thürlimann, B. (eds) Adjuvant Therapy of Breast Cancer V. Recent Results in Cancer Research, vol 140. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79278-6_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-79278-6_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-79280-9
Online ISBN: 978-3-642-79278-6
eBook Packages: Springer Book Archive